Shield TherapeuticsSTU:1JS 3-Year ROIIC % is 128.28 as of Dec. 2025, which is 773% above its 10-year median of 14.70. The stock has 5 warning signs investors should review. Among 943 Drug Manufacturers companies, Shield Therapeutics ranks better than 92.05% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Shield Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 128.28%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Shield Therapeutics's 3-Year ROIIC % or its related term are showing as below:
STU:1JS's 3-Year ROIIC % is ranked better than 92.05% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.74
vs STU:1JS: 128.28
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Shield Therapeutics 3-Year ROIIC % Related Terms
Shield Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1JS vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's 3-Year ROIIC % falls into.
Shield Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -8.583 (Dec. 2025) - -29.874 (Dec. 2022) )
/
( 39.236 (Dec. 2025) - 22.904 (Dec. 2022) )
=
21.291
/
16.332
=
130.36%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Shield Therapeutics (STU:1JS) has a 3-Year ROIIC % of 128.28 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Shield Therapeutics and its competitors. This is 773% above median its historical median of 14.70. According to the industry distribution chart, Shield Therapeutics ranks #75 out of 943 companies in the Drug Manufacturers industry, placing it in the top 8%.
Is Shield Therapeutics' 3-Year ROIIC % too high?
Shield Therapeutics' current 3-Year ROIIC % of 128.28 is 773% above median its 10-year median of 14.70. The Drug Manufacturers industry median 3-Year ROIIC % is 3.74. Shield Therapeutics' value of 128.28 is 3329.9% above this industry median. Based on the distribution chart, Shield Therapeutics ranks #75 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Shield Therapeutics' 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #75 out of 943 companies for 3-Year ROIIC %. This places Shield Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.74. Shield Therapeutics' value of 128.28 is 3329.9% above this benchmark. While the company's 10-year median is 14.70 vs. the industry median of 3.74, Shield Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.74, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shield Therapeutics's current 3-Year ROIIC % of 128.28 is 3329.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current 3-Year ROIIC % is 128.28, which is 773% above median its own 10-year median of 14.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current 3-Year ROIIC % is 128.28, which is 773% above median its 10-year median of 14.70 and 3329.9% above the Drug Manufacturers industry median of 3.74. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current 3-Year ROIIC % is 128.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1JS has been successfully added to your 